anim
model
studi
opiat
grow
interest
examin
shortterm
safeti
buprenorphin
implant
fischer
rat
treat
excess
dose
cholesteroltriglycerid
suspens
buprenorphin
singl
inject
mgkg
afford
clinic
signific
blood
level
analgesia
day
chemistri
hematolog
coagul
urinalysi
valu
excess
dose
druglipid
suspens
within
normal
limit
histopatholog
find
unremark
skin
underli
tissu
surround
drug
inject
unremark
report
result
longterm
followup
studi
femal
rat
inject
mgkg
evalu
show
abnorm
find
could
attribut
drug
lipid
suspens
result
confirm
safeti
cholesteroltriglycerid
carrier
system
subcutan
drug
deliveri
laboratori
anim
suggest
model
may
use
studi
longterm
effect
opiat
therapi
model
longact
drug
therapi
laboratori
anim
manag
ad
drug
feed
water
suppli
util
strategi
decreas
food
water
mixtur
may
releas
inadvert
environ
drug
highli
regul
control
substanc
altern
approach
focus
longact
drug
implant
made
combin
drug
biodegrad
implant
compos
lipid
polym
polym
studi
dug
carrier
neurooncolog
side
effect
gener
modest
local
polym
implant
neural
tissu
less
known
biodegrad
polym
subcutan
sc
deliveri
chemotherapi
moder
sever
inflammatori
reaction
report
sc
implant
polymeropi
construct
fewer
advers
event
report
lipid
drug
carrier
kent
describ
implant
cholesterol
matrix
deliv
larg
molecul
insulin
growth
hormon
grant
cowork
demonstr
phospholipidmorphin
liposom
prolong
activ
greater
safeti
mice
free
drug
lipidbas
carrier
strategi
refin
deliveri
sever
opiat
pontani
misra
describ
cholesteroltriglycerid
matrix
longterm
deliveri
drug
treat
chronic
pain
opiat
addict
cholesteroltriglycerid
vehicl
appear
provid
promis
carrier
examin
deliveri
antibiot
antiinflammatori
drug
analges
pain
manag
anim
yet
solid
cholesterolbas
implant
sequest
interstiti
tissu
creat
drugcontain
depot
uncertain
releas
kinet
subsequ
studi
demonstr
cholesterol
suspens
provid
consist
releas
kinet
littl
evid
tissu
sequestr
effect
examin
safeti
cholesteroltriglycerid
suspens
buprenorphin
mice
rat
use
us
food
drug
administr
fda
target
anim
safeti
ta
drugdevelop
protocol
histopatholog
examin
perform
mice
rat
treat
tenfold
excess
intend
dose
drug
control
anim
follow
drug
trial
examin
includ
studi
sc
area
drug
implant
unremark
signific
differ
drugtreat
control
anim
examin
longterm
safeti
lipid
suspens
dose
group
femal
rat
intend
dose
mgkg
mgkg
drug
control
drugfre
matrix
rat
maintain
month
euthan
provid
longterm
clinic
patholog
data
shown
follow
report
signific
differ
weight
laboratori
chemistri
hematolog
necroscopi
report
drugtreat
control
rat
studi
approv
john
hopkin
univers
institut
anim
care
use
committe
iacuc
iacuc
protocol
compli
nation
research
council
guid
care
use
laboratori
anim
fulfil
requir
associ
assess
accredit
laboratori
anim
care
intern
program
fischer
rat
femal
g
obtain
tacon
farm
hudson
ny
hous
environment
control
room
maintain
temperatur
f
monthli
health
surveil
conduct
soiledbed
sentinel
system
sentinel
rat
neg
pneumonia
viru
mice
reoviru
sendai
viru
lymphocyt
choriomening
viru
rat
coronaviru
sialodacryoaden
viru
rat
parvoviru
kilham
rat
viru
toolan
parvoviru
rat
theiloviru
ciliaassoci
respiratori
bacillu
pneumocysti
carinii
mycoplasma
pulmoni
pinworm
throughout
studi
facil
maintain
rel
humid
dark
cycl
pm
anim
group
hous
per
cage
quarantin
acclim
period
base
groupsex
design
anim
quarantin
acclim
six
day
prior
dose
diseaserel
sign
note
quarantineacclim
period
prior
place
test
clinic
veterinarian
approv
anim
studi
use
anim
appear
normal
prior
dose
drug
inject
rat
hous
per
cage
day
prevent
redos
coprophagi
day
rat
hous
per
cage
hous
consist
soft
fiber
contact
bed
carefresh
natur
bed
ferndal
wa
ad
libitum
access
harlan
teklad
certifi
global
rodent
diet
harlan
teklad
indianapoli
ad
libitum
access
drink
water
baltimor
citi
water
system
baltimor
md
dispos
water
bottl
anim
provid
ad
libitum
access
harlan
teklad
certifi
global
rodent
diet
harlan
teklad
indianapoli
rat
provid
enrich
devic
polycarbon
red
tube
bio
servic
uden
nl
static
microisol
cage
chang
weekli
design
label
dose
mgkg
buprenorphin
provid
day
clinic
signific
blood
level
drug
establish
bioequival
trial
efficaci
studi
use
male
femal
rat
femal
rat
studi
divid
group
rat
provid
mgkg
buprenorphin
cage
side
evalu
conduct
twice
daili
morn
afternoon
two
week
veterinarian
blind
dose
group
rat
evalu
weekli
interv
staff
veterinari
servic
thereaft
rat
schedul
harvest
clinic
patholog
studi
year
actual
month
anomali
abnorm
discov
necroscopi
examin
histopatholog
hypothesi
rat
treat
highest
dose
would
tissu
chang
near
inject
site
found
control
group
limit
stress
associ
constrain
consciou
anim
sc
inject
rat
anesthet
intraperiton
ip
solut
ketamin
mgkg
xylazin
mgkg
salin
solut
contain
ethyl
alcohol
rat
inject
design
dose
test
articl
buprenorphinefre
control
suspens
recov
anesthesia
dose
administ
sc
middors
area
cm
rostral
surgic
incis
use
gaug
needl
bd
franklin
nj
attach
ml
bd
tuberculin
syring
follow
dose
administr
anim
transfer
clean
cage
heat
pad
recov
anim
regain
conscious
demonstr
normal
movement
absenc
sign
distress
return
home
cage
posttreat
distress
observ
patholog
month
time
point
euthanasia
administ
co
inhal
blood
collect
exsanguin
cardiocentesi
follow
thoracotomi
hematolog
examin
cbc
includ
red
blood
cell
rbc
count
hemoglobin
hematocrit
mean
corpuscular
volum
mean
corpuscular
hemoglobin
mean
corpuscular
hemoglobin
concentr
platelet
count
white
blood
cell
wbc
count
differenti
blood
cell
count
blood
smear
serum
chemistri
test
includ
glucos
urea
nitrogen
creatinin
total
protein
albumin
globulin
calcul
total
cholesterol
alanin
aminotransferas
alkalin
phosphatas
aspart
aminotransferas
calcium
sodium
potassium
chlorid
phosphat
necropsi
perform
anim
tissu
histopatholog
immers
fix
individu
label
contain
contain
neutralbuff
formalin
transfer
perform
document
histolog
lab
contain
label
studi
number
date
group
number
anim
number
organ
weight
includ
adren
brain
heart
kidney
liver
ovari
spleen
uteru
cervix
histopatholog
assess
gross
lesion
dorsal
skin
surround
inject
site
previous
describ
esophagu
heart
kidney
liver
lung
lymph
node
spleen
statist
analys
mean
standard
deviat
n
conduct
organ
weight
clinic
patholog
data
compar
treat
group
control
group
lack
variat
data
see
result
analys
includ
oneway
analysi
varianc
anova
dunnett
ttest
use
rat
surviv
schedul
termin
date
sign
excess
groom
selfgnaw
note
one
rat
mgkg
dose
group
day
posttreat
observ
note
find
comment
anim
chart
evid
open
wound
sinc
day
remark
chang
anim
behavior
outcom
weight
three
group
similar
g
g
g
rat
mgkg
dose
group
respect
signific
differ
organ
weight
liver
spleen
heart
kidney
brain
adren
gland
uteru
cervix
ovari
signific
differ
hematolog
valu
three
group
averag
group
differ
note
two
clinic
chemistri
valu
blood
urea
nitrogen
bun
valu
mgdl
control
mgkg
group
respect
alkalin
phosphatas
alp
valu
ul
respect
gross
examin
rat
vehicl
control
group
mgkg
mild
dorsal
neckinterscapular
skin
excori
mild
crust
inject
site
could
distinguish
surround
skin
rat
microscop
examin
one
rat
control
group
one
rat
mgkg
dose
group
mild
ulcer
chronic
dermat
involv
dorsal
neckinterscapular
skin
mildmoder
hemorrhag
serosuppur
crust
consist
recent
injuri
possibl
relat
conspecif
trauma
aggress
neck
groom
cage
mate
find
includ
one
rat
control
group
cystic
uterin
endometri
polyp
less
diamet
one
rat
mgkg
dose
group
ovarian
cyst
diamet
mild
cardiac
chang
inflamm
degener
fibrosi
mild
nephropathi
pigment
tubul
epithelium
mild
lung
inflammatori
chang
microminer
lung
vasculatur
observ
group
pigment
macrophag
lymph
node
spleen
observ
rat
one
rat
mgkg
group
ovarian
cyst
one
vehicl
control
group
uterin
polyp
pigment
variou
site
consist
hemosiderin
hematoidin
ceroidlipofuscin
uniqu
microscop
lesion
associ
test
articl
object
studi
evalu
longterm
safeti
lipid
suspens
buprenorphin
deliveri
opiat
analges
femal
rat
femal
rat
chosen
longterm
trial
femal
rat
may
increas
suscept
opiat
although
sex
differ
fulli
determin
result
confirm
lipidbas
deliveri
system
caus
signific
advers
effect
rat
model
one
rat
illustr
sign
nausea
day
sign
observ
previous
incid
nausea
model
appear
similar
observ
incid
nausea
human
patient
treat
opioid
analgesia
remark
differ
hematolog
paramet
control
drugtreat
rat
clinic
chemistri
valu
serum
bun
alk
rat
given
mgkg
dose
decreas
compar
control
valu
rat
given
intend
dose
mgkg
clinic
signific
differ
remain
uncertain
weight
loss
cite
deterr
use
postsurg
buprenorphin
analgesia
link
signific
morbid
secondari
gastrointestin
blockag
associ
hardwood
bed
number
report
describ
weight
loss
rat
treat
buprenorphin
without
refer
bed
use
experi
report
use
hardwood
bed
without
refer
previou
report
associ
hardwood
bed
pica
previou
studi
demonstr
risk
picarel
gastric
distress
control
appropri
choic
bed
signific
differ
organ
weight
appear
drugtreat
rat
bodi
weight
also
similar
studi
report
confirm
observ
result
studi
compromis
failur
includ
male
rat
use
higher
dose
drug
includ
salinecontrol
group
establish
safeti
lipid
suspens
appear
clinic
signific
treatmentrel
effect
follow
subcutan
inject
extend
releas
lipid
suspens
buprenorphin
mgkg
dose
although
sever
clinic
patholog
find
exceed
normal
limit
correl
chang
find
bodi
weight
clinic
observ
organ
weight
microscop
evalu
tissu
data
use
support
find
studi
avail
correspond
author
upon
request
michael
guarnieri
own
signific
financi
interest
animalges
lab
